Aberdeen Group’s CONMED CNMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-141,186
Closed -$8.53M 959
2025
Q1
$8.53M Buy
141,186
+5,249
+4% +$338K 0.02% 602
2024
Q4
$9.4M Sell
135,937
-29,841
-18% -$2.08M 0.02% 522
2024
Q3
$11.9M Sell
165,778
-14,859
-8% -$1.05M 0.02% 487
2024
Q2
$12.5M Sell
180,637
-8,232
-4% -$600K 0.02% 473
2024
Q1
$15.1M Sell
188,869
-23,985
-11% -$2.14M 0.03% 471
2023
Q4
$23.3M Sell
212,854
-22,338
-9% -$2.31M 0.05% 354
2023
Q3
$23.7M Sell
235,192
-48,704
-17% -$5.6M 0.06% 293
2023
Q2
$38.6M Sell
283,896
-127,957
-31% -$15.6M 0.09% 211
2023
Q1
$42.8M Sell
411,853
-40,485
-9% -$3.92M 0.11% 192
2022
Q4
$40.1M Buy
452,338
+99,564
+28% +$8.26M 0.11% 204
2022
Q3
$28.3M Buy
352,774
+22,644
+7% +$2.14M 0.08% 253
2022
Q2
$33M Buy
330,130
+60,810
+23% +$7.3M 0.1% 212
2022
Q1
$40.3M Sell
269,320
-75,191
-22% -$10.5M 0.1% 208
2021
Q4
$48.8M Buy
344,511
+30,798
+10% +$4.36M 0.11% 193
2021
Q3
$41.3M Buy
313,713
+42,134
+16% +$5.51M 0.09% 223
2021
Q2
$37.3M Buy
+271,579
New +$37.2M 0.08% 233

Other funds holding CNMD

Aberdeen Group's CNMD Position: Q2 2025 in Review

Aberdeen Group sold out of CONMED (CNMD) in Q2 2025, closing a stake of 141,186 shares — an estimated $8.53M sold.

Aberdeen Group first reported a position in CNMD in Q2 2021 and held it in 16 quarters. The position peaked at $48.8M in Q4 2021. 277 funds tracked by Wall St. Rank hold CNMD as of Q2 2025.

  • Aberdeen Group reported no remaining CONMED position as of Q2 2025 after selling out during the quarter.
  • Aberdeen Group sold 141,186 CONMED shares in Q2 2025, an estimated $8.53M.
  • Aberdeen Group first reported a position in CONMED in Q2 2021 and held it in 16 quarters.
  • Aberdeen Group's CONMED position peaked at $48.8M in Q4 2021.
  • 277 funds tracked by Wall St. Rank held CONMED as of Q2 2025.

Based on Aberdeen Group's 13F filing for Q2 2025, filed 24 Jul 2025.